CN102370640A - Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same - Google Patents
Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same Download PDFInfo
- Publication number
- CN102370640A CN102370640A CN201010255751XA CN201010255751A CN102370640A CN 102370640 A CN102370640 A CN 102370640A CN 201010255751X A CN201010255751X A CN 201010255751XA CN 201010255751 A CN201010255751 A CN 201010255751A CN 102370640 A CN102370640 A CN 102370640A
- Authority
- CN
- China
- Prior art keywords
- hemodialysis
- preparation
- amino acid
- acid
- isoleucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a compound amino acid preparation for hemodialysis and a hemodialysis preparation containing the same. The invention provides a preparation for modulating disorder of plasma aminogram of hemodialysis patients by using a plurality of essential amino acids and semi-essential amino acids, specifically relates to a solid powder form or liquid bicarbonate hemodialysis preparation used for treating nephrosis and containing compound amino acids, and especially to a hemodialysis preparation containing L-leucine, L-isoleucine, L-valine, L-threonine, L-phenylalanine, L-methionine, L-tryptophan, L-lysine, L-histidine, L-arginine and a pH conditioning agent (e.g., acetic acid, citric acid, malic acid, lactic acid and hydrochloric acid) and a preparation method thereof. The hemodialysis preparation further contains sodium chloride, potassium chloride, calcium chloride, magnesium chloride and sodium bicarbonate, and can also include glucose. Compared to conventional bicarbonate hemodialysis preparations, the preparation provided in the invention has the advantages of partly modulating disorder of plasma aminogram of hemodialysis patients and reducing side effects in hemodialysis treatment.
Description
Technical field
The present invention relates to the amino acid that a kind of hemodialysis is used, be exactly specifically the kidney patient in hemodialysis with each seed amino acid as the hemodialysis of nutritional supplementation with preparation and preparation method thereof.
Background technology
As everyone knows; The impairment of renal function can increase the underfed chance of occurrence of nephrotic; When many evidence acute renal failures and chronic renal failure, protein and amino acid metabolism are unusual, show as the interior amino acid levels of blood plasma amino acid levels and cell and occur unusual.Relevant 1. loss of appetite of its reason with multiple factor, vomiting, diarrhoea, long-term low protein diet makes and must reduce by aminoacid.2. the nonessential ability of amino acid of RE descends, and causes nonessential aminoacid to raise.3. renal failure and hemodialysis patients often merge VitB
6Shortage, cause the concentration of branched-chain amino acid such as leucine, isoleucine, valine to reduce, again because the amino acid molecular amount is less; Very easily removed by hemodialysis; Many clinical researches prove, each hemodialysis, and the patient will lose the aminoacid of 5-8g; Wherein essential amino acids is reduced to 16.85 ± 4.09mg% after the dialysis by preceding the 22.4 ± 3.3mg% of dialysis, thereby causes the more tangible disorder of amino acid metabolism of uremic patient.
Summary of the invention
For above-mentioned reasons, the present invention has added multiple to very important essential amino acids of kidney patient and semi-dispensable amino acid in original traditional dialysis preparation.Can regulate the amino acid whose balance of hemodialysis process effectively, improve in the hemodialysis or patient's ill symptoms behind the hemodialysis.
In order to achieve the above object; The present invention proposes a kind of contain amino acid, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, stabilizing agent or pH regulator agent (can be acetic acid, lactic acid, malic acid, citric acid, hydrochloric acid etc.); Preparation is used in the hemodialysis that also can comprise the Fructus Vitis viniferae composition; Provided by the inventionly contain the amino acid hemodialysis and use preparation; Can be to contain the amino acid hemodialysis of above-mentioned electrolyte ingredient with powderous preparations and liquid preparation, also can be not above-mentioned four kinds of products that contain the hemodialysis of electrolyte ingredient with amino acid powderous preparations and liquid preparation.
The objective of the invention is to realize through following technical scheme.
Preparation is used in amino acid hemodialysis provided by the invention, is solid-state powderous preparations and liquid preparation, and main component does; L-leucine, L-isoleucine, L-valine, L-methionine, L-phenylalanine, L-lysine, L-threonine, L-tryptophan, L-histidine, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium bicarbonate, PH regulator (like malic acid, citric acid, lactic acid, acetic acid, hydrochloric acid etc.) also can comprise glucose and L-arginine.Dissolve at the clinical liquid that should be prepared into following concentration when carrying out hemodialysis; L-leucine 5-15mg/L, L-isoleucine 3-12mg/L, L-valine 3-12mg/L, L-methionine 6-18mg/L, L-phenylalanine 7-22mg/L, L-lysine 3-12mg/L, L-threonine 2-9mg/L, L-tryptophan 1-5mg/L, L-histidine 2-16mg/L, L-arginine 0-20mg/L, Na
+130-145mmol/L, K
+0-4mmol/L, Ca
2+1-3mmol/L, Mg
2+0.25-1.0mmol/L, Cl
-90-120mmol/L, HCO
-25-40mmol/L, pH regulator agent 1-10mmol/L, glucose 0-5g/L
Each composition preferred concentration of the present invention does; L-leucine 11.43mg/L, L-isoleucine 8.3mg/L, L-valine 8.52mg/L, L-methionine 12.5mg/L, L-phenylalanine 14.5mg/L, L-lysine 8.8mg/L, L-threonine 5.2mg/L, L-tryptophan 3.6mg/L, L-histidine 6.23mg/L, L-arginine 0 or 10.4mg/L, Na
+138mmol/L, K
+2mmol/L, Ca
2+1.5mmol/L, Mg
2+0.5mmol/L, Cl
-110mmol/L, HCO
-35mmol/L, pH regulator agent 2mmol/L, glucose 0.2g/L
The invention provides a kind of hemodialysis with the compound amino acid supplement and contain the solid powder product preparation method of the hemodialysis of amino acid with preparation; The raw material of being selected for use in the present invention prescription through sieving, is sealed up for safekeeping after the mixing in packing container, during application with the water for dialysis dissolving and be diluted to above-mentioned concentration.
The invention provides a kind of hemodialysis with the compound amino acid supplement and contain the method for preparing of the hemodialysis of amino acid with the fluid product of preparation; With raw material of selecting for use in the present invention's prescription and purified water combination, through dissolving, filter the back embedding in packing container, be diluted to above-mentioned concentration with dialysis water during application.
The present invention compares with the similar preparation of prior art and has the following advantages
1. preparation provided by the invention and traditional hemodialysis with preparation relatively have the disorderly effect of obvious suppression blood plasma aminogram, can prevent the nephrotic blood plasma is amino acid whose when carrying out dialysis treatment to lose, and can improve the nutritional status of dialysis patient.In clinical respectively with the hemodialysis of the present invention preparation with preparation and traditional hemodialysis preparation, through the concentration of essential amino acids in the amino-acid analyzer mensuration blood plasma.Relatively the concentration results of essential amino acids is following in the patient's blood plasma of dialysis front and back:
(umol/L)
| Aminoacid | Key health people | Before the dialysis | After the tradition dialysis | After the present invention's dialysis |
| The L-isoleucine | 89.6±15.4 | 86.3±39.6 | 63.4±33.8 | 81.4±17.6 |
| The L-leucine | 159.7±56.5 | 137.7±60.5 | 115.5±45.1 | 152.7±29.1 |
| The L-threonine | 620.0±110.3 | 548.4±130.3 | 430.9±113.3 | 532.2±105.3 |
| The L-valine | 232.5±47.5 | 227.5±108.8 | 108.8±61.8 | 152.3±43.3 |
| The L-phenylalanine | 78.1±13.4 | 140.9±47.2 | 96.4±26.4 | 88.3±23.0 |
| The L-methionine | 35.9±8.0 | 35.9±8.0 | 25.5±9.9 | 29.9±5.7 |
Continuous table (umol/L)
| L-lysine | 187.5±66.5 | 177.7±67.2 | 110.3±35.0 | 133.6±27.8 |
| The L-histidine | 147.2±25.5 | 126.8±44.3 | 76.0±30.4 | 101.6±12.9 |
| The L-arginine | 109.5±22.4 | 95.1±39.9 | 49.1±20.7 | 73.7±25.3 |
2. clinical effectiveness is definite.Have a headache in the hemodialysis, cardiopalmus, uncomfortable in chest and side effect incidence rates such as hypertension or hypotension all obviously reduce.
The specific embodiment
Embodiment 1.
Press the row weight portion respectively and get following various amino acid starting material; L-leucine 12.9g, L-isoleucine 9.3g, L-lysine 10g, L-methionine 14.14g, L-phenylalanine 16.15g, L-valine 9.3g, L-threonine 5.8g, L-tryptophan 3.8g, L-histidine 6.4g, L-arginine 11.6g; Mix homogeneously after sieving is packaged in the container.
Instance 2.
Press the row weight portion respectively and get following various amino acid starting material; L-leucine 12.9g, L-isoleucine 9.3g, L-lysine 10g, L-methionine 14.1g, L-phenylalanine 16.1g, L-valine 9.6gL-threonine 5.8g, L-tryptophan 3.8g, L-histidine 6.4g, L-arginine 11.6g; Place purified water to dissolve; Neutral with pH regulator agent acid adjustment basicity to closely; After the aseptic filtration with the concentrated solution fill in container, seal after charging into nitrogen.
Instance 3.
Press the row weight portion and get following various amino acid starting material; L-leucine 14.6g, L-isoleucine 10.6g, L-lysine 11.3g, L-methionine 16g, L-phenylalanine 18.2g, L-valine 10.9g/, L-threonine 6.6g, L-tryptophan 4.3g, L-histidine 7.3g; Mix homogeneously after sieving respectively is packaged in the container.
Instance 4.
Press the row weight portion and get following various amino acid starting material; L-leucine 12.9g, L-isoleucine 9.3g, L-lysine 10g, L-methionine 14.1g, L-phenylalanine 16.1g, L-valine 9.6g, L-threonine 5.8g, L-tryptophan 3.8g, L-histidine 6.4g, L-arginine 11.6g; And sodium chloride, potassium chloride, calcium chloride, magnesium chloride, the pH regulator agent of recipe quantity, also can comprise glucose; Mix homogeneously after sieving respectively is packaged in the container.
After sieving, the sodium bicarbonate that other gets recipe quantity is packaged in the container.
Instance 5.
Press the row weight portion and get following various amino acid starting material; L-leucine 14.6g, L-isoleucine 10.6g, L-lysine 11.3g, L-methionine 16g, L-phenylalanine 18.2g, L-valine 10.9g, L-threonine 6.6g, L-tryptophan 4.3g, L-histidine 7.3g; And sodium chloride, potassium chloride, calcium chloride, magnesium chloride, the pH regulator agent of recipe quantity, also can comprise glucose; Mix homogeneously after sieving respectively is packaged in the container.
Other gets and is packaged in the container after the recipe quantity sodium bicarbonate sieves.
Instance 6
Press the row weight portion and get following various amino acid starting material; L-leucine 12.9g, L-isoleucine 9.3g, L-lysine 10g, L-methionine 14.1g, L-phenylalanine 16.1g, L-valine 9.6g, L-threonine 5.8g, L-tryptophan 3.8g, L-histidine 6.4g, L-arginine 11.6g; And sodium chloride, potassium chloride, calcium chloride, magnesium chloride, the pH regulator agent of recipe quantity, also can comprise glucose; Be dissolved in the purified water, embedding is in container after filtering.
The sodium bicarbonate that other gets recipe quantity is dissolved in the purified water, and embedding is in container after filtering.
Instance 7
Press the row weight portion and get following various amino acid starting material; L-leucine 14.6g, L-isoleucine 10.6g, L-lysine 11.3g, L-methionine 16g, L-phenylalanine 18.2g, L-valine 10.9g, L-threonine 6.6g, L-tryptophan 4.3g, L-histidine 7.3g; And sodium chloride, potassium chloride, calcium chloride, magnesium chloride, the pH regulator agent of recipe quantity, also can comprise glucose; Be dissolved in the purified water, embedding is in container after filtering.
Other gets the recipe quantity sodium bicarbonate and is dissolved in the purified water, and embedding is in container after filtering.
Claims (6)
1. amino acid is used in hemodialysis; It is characterized in that forming, when clinical practice, should be prepared into following concentration: L-leucine 5-15mg/L, L-isoleucine 3-12mg/L, L-lysine 3-12mg/L, L-methionine 6-18mg/L, L-phenylalanine 7-22mg/L, L-valine 3-12mg/L, L-threonine 2-9mg/L, L-tryptophan 1-5mg/L, L-histidine 2-10mg/L, L-arginine 0-20mg/L by following several seed amino acids
2. preparation is used in the hemodialysis that contains amino acid; It is characterized in that by following several seed amino acids and sodium chloride; Potassium chloride, calcium chloride, magnesium chloride; Sodium bicarbonate; The pH regulator agent is formed, and also can comprise glucose, when clinical practice, should be prepared into following concentration: L-leucine 5-15mg/L, L-isoleucine 3-12mg/L, L-lysine 3-12mg/L, L-methionine 6-18mg/L, L-phenylalanine 7-22mg/L, L-valine 3-12mg/L, L-threonine 2-9mg/L, L-tryptophan 1-5mg/L, L-histidine 2-10mg/L, L-arginine 0-20mg/L, Na+130-145mmol/L, K
+0-4mmol/L, Ca
2+1-3mmol/L, Mg
2+0.25-1.0mmol/L, Cl
-90-120mmol/L, HCO
-25-40mmol/L, pH regulator agent 1-10mmol/L, glucose 0-5g/L
3. use the compound amino acid supplement according to the hemodialysis of claim 1, each constituent concentration is when clinical practice: L-leucine 11.43mg/L, L-isoleucine 8.3mg/L, L-lysine 8.83mg/L, L-methionine 12.5mg/L, L-phenylalanine 14.55mg/L, L-valine 8.52mg/L, L-threonine 5.2mg/L, L-tryptophan 3.6mg/L, L-histidine 6.23mg/L, L-arginine 0-10.39mg/L, pH regulator agent 1-4mmg/L, glucose 0.2g/L
4. use preparation according to the amino acid hemodialysis that contains of claim 1.2, the various compositions of said preparation should be prepared into following concentration when clinical clinical practice: L-leucine 11.43mg/L, L-isoleucine 8.3mg/L, L-lysine 8.83mg/L, L-methionine 12.5mg/L, L-phenylalanine 14.55mg/L, L-valine 8.52mg/L, L-threonine 5.2mg/L, L-tryptophan 3.6mg/L, L-histidine 6.23mg/L, L-arginine 0-10.39mg, Na
+138mmol/L, K
+2.0mmol/L, Ca
2+1.5mmol/L, Mg
2+0.5mmol/L, Cl
-110mmol/L, HCO
-35mmol/L, pH regulator agent 1-4mmol/L, glucose 0.2g/L
5. the hemodialysis of using amino acid according to the hemodialysis of claim 1-4 and containing amino acid uses the pH regulator agent described in the composition of preparation to be: acetic acid (or glacial acetic acid) citric acid, malic acid, lactic acid or hydrochloric acid, can use separately also can work in coordination mixes and uses.
6. it also can be the liquid condition preparation as the powder of solid state that preparation is used in the hemodialysis of using amino acid according to claim 1-5 hemodialysis and containing amino acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010255751XA CN102370640A (en) | 2010-08-18 | 2010-08-18 | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010255751XA CN102370640A (en) | 2010-08-18 | 2010-08-18 | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102370640A true CN102370640A (en) | 2012-03-14 |
Family
ID=45790227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010255751XA Pending CN102370640A (en) | 2010-08-18 | 2010-08-18 | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102370640A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638526A (en) * | 2013-12-12 | 2014-03-19 | 河北紫薇山制药有限责任公司 | Preparation for purifying blood as well as preparation method and application thereof |
| CN104586884A (en) * | 2015-01-09 | 2015-05-06 | 李淑秀 | Novel hemodialysis concentrate |
| CN106176730A (en) * | 2015-05-05 | 2016-12-07 | 刘力 | The amino acid whose medical composition and its use of 9AA containing chiral photo-isomerisation compound |
| CN106511339A (en) * | 2015-09-09 | 2017-03-22 | 华仁药业股份有限公司 | Dual-chamber bag amino acid peritoneal dialysis solution and preparation method thereof |
| CN107456462A (en) * | 2016-06-02 | 2017-12-12 | 山东威高药业股份有限公司 | Amino acid haemodialysis concentrate |
| AU2017300740B2 (en) * | 2016-07-22 | 2023-05-11 | Fresenius Medical Care Deutschland Gmbh | HD acid concentrate with amino acids |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1122106A (en) * | 1994-01-21 | 1996-05-08 | 巴克斯特国际有限公司 | Peritoneal dialysis solutions containing maltodextrins and amino acids |
| US5670176A (en) * | 1992-12-22 | 1997-09-23 | Baxter International Inc. | Amino acid solutions for treatment of peritoneal dialysis patients |
| US5827820A (en) * | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
| US6830692B1 (en) * | 1999-09-20 | 2004-12-14 | Degussa Ag | Amino acid composition for hemodialysis |
| US20050148647A1 (en) * | 2003-10-31 | 2005-07-07 | Landry Donald W. | Hemodialysis solutions and uses thereof |
| CN1813718A (en) * | 2005-12-14 | 2006-08-09 | 于力犁 | Dialysate amino acid powder/liquid, and its compound dialysate power/liquid and preparing method |
-
2010
- 2010-08-18 CN CN201010255751XA patent/CN102370640A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827820A (en) * | 1992-04-06 | 1998-10-27 | Baxter International Inc. | Aqueous peritoneal dialysis solution |
| US5670176A (en) * | 1992-12-22 | 1997-09-23 | Baxter International Inc. | Amino acid solutions for treatment of peritoneal dialysis patients |
| CN1122106A (en) * | 1994-01-21 | 1996-05-08 | 巴克斯特国际有限公司 | Peritoneal dialysis solutions containing maltodextrins and amino acids |
| US6830692B1 (en) * | 1999-09-20 | 2004-12-14 | Degussa Ag | Amino acid composition for hemodialysis |
| US20050148647A1 (en) * | 2003-10-31 | 2005-07-07 | Landry Donald W. | Hemodialysis solutions and uses thereof |
| CN1813718A (en) * | 2005-12-14 | 2006-08-09 | 于力犁 | Dialysate amino acid powder/liquid, and its compound dialysate power/liquid and preparing method |
Non-Patent Citations (4)
| Title |
|---|
| 李冀军等: "平衡型氨基酸透析液对维持性血液透析患者血浆游离氨基酸含量的影响", 《氨基酸和生物资源》 * |
| 王军等: "氨基酸腹膜透析对腹透患者营养状况的影响", 《肾脏病与透析肾移植杂志》 * |
| 田康等: "CAPD病人从透析液中丢失氨基酸分析", 《中国医师杂志》 * |
| 谭永红: "肾透析A、B液的配制与质量标准", 《华西药学杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103638526A (en) * | 2013-12-12 | 2014-03-19 | 河北紫薇山制药有限责任公司 | Preparation for purifying blood as well as preparation method and application thereof |
| CN104586884A (en) * | 2015-01-09 | 2015-05-06 | 李淑秀 | Novel hemodialysis concentrate |
| CN106176730A (en) * | 2015-05-05 | 2016-12-07 | 刘力 | The amino acid whose medical composition and its use of 9AA containing chiral photo-isomerisation compound |
| CN106511339A (en) * | 2015-09-09 | 2017-03-22 | 华仁药业股份有限公司 | Dual-chamber bag amino acid peritoneal dialysis solution and preparation method thereof |
| CN106511339B (en) * | 2015-09-09 | 2020-01-21 | 华仁药业股份有限公司 | Double-chamber bag amino acid peritoneal dialysis solution and preparation method thereof |
| CN107456462A (en) * | 2016-06-02 | 2017-12-12 | 山东威高药业股份有限公司 | Amino acid haemodialysis concentrate |
| AU2017300740B2 (en) * | 2016-07-22 | 2023-05-11 | Fresenius Medical Care Deutschland Gmbh | HD acid concentrate with amino acids |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102370640A (en) | Compound amino acid preparation for hemodialysis and hemodialysis preparation containing same | |
| Ash et al. | A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient | |
| Mortelmans et al. | Intradialytic parenteral nutrition in malnourished hemodialysis patients: a prospective long‐term study | |
| CN102370990A (en) | Blood purification preparation using malic acid as pH conditioning agent, and preparation method and application thereof | |
| KR101457055B1 (en) | Peritoneal dialysate | |
| JP2017014287A5 (en) | Stabilization of high-pressure steam sterilized peripheral intravenous nutrition | |
| US11896569B2 (en) | Compositions comprising amino acids for use in the treatment of mucositides in neoplasia patients undergoing radiation therapy and/or chemotherapy | |
| CN107095847A (en) | It is mixed with the peripheral vein administrable nutrition infusion of vitamin | |
| FI88581B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN NAERINGSTILLSATS FOER BEHANDLING AV UREMI | |
| CN105661235A (en) | Beverage for supplementing compound nutrients and production method thereof | |
| JP2007056013A (en) | Supplementary liquid for dialysis | |
| JP5847712B2 (en) | Cell protection of dialysis patients by administration of creatine compounds | |
| CA2893478C (en) | Dialysis composition | |
| CN103638526B (en) | A kind of blood purification preparation and preparation method thereof and application | |
| CN106511339B (en) | Double-chamber bag amino acid peritoneal dialysis solution and preparation method thereof | |
| AU751556B2 (en) | Supplement for dialysis patients | |
| CN105640946A (en) | Amino-acids (15) lactate peritoneal dialysis fluid medicinal composition | |
| CN105640948A (en) | Essential amino-acids lactate peritoneal dialysis fluid medicinal composition | |
| CN106262008A (en) | Prevent exsanguine polypeptide capsule and preparation method thereof | |
| CN106267141A (en) | Anticoagulation antineoplastic polypeptide lyophilized powder capsule and preparation method thereof | |
| CN104940195A (en) | Pharmaceutical composition containing alanyl glutamine and compound amino acid | |
| CN102940628A (en) | Compound amino acid injection and preparation method thereof | |
| CN107456462A (en) | Amino acid haemodialysis concentrate | |
| JPS6330413A (en) | Composition for amino acid transfusion | |
| CN105640945A (en) | Low-calcium peritoneal dialysis fluid pharmaceutical composition containing essential amino-acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: HAINAN WANZHOU GREEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YU LILI Effective date: 20120516 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100022 CHAOYANG, BEIJING TO: 571500 WANNING, HAINAN PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20120516 Address after: 571500. Water sounds in Le Town, Wanning City, Hainan Province Applicant after: Hainan Wanzhou Green Pharmaceutical Co., Ltd. Address before: 100022, room 4, building 54, Hua Tengyuan, East Third Ring Road, Chaoyang District, Beijing, 2205 Applicant before: Yu Lili |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120314 |